How Does Kliovance Work in the Body
Chemical Composition, Mechanism of Action & Metabolic Effects Explained
Key Takeaways: How Kliovance Works
- Active ingredients: Estradiol 1 mg (oestrogen) and norethisterone acetate 0.5 mg (progestogen).
- Dual mechanism: Estradiol relieves menopausal symptoms and prevents bone loss; norethisterone protects the womb lining from excessive growth.
- Continuous combined regimen: Daily intake without a break avoids monthly bleeding and reduces endometrial cancer risk.
- Onset & timeline: Symptom relief typically starts within 2–4 weeks; full bone protection requires months of consistent use.
- Metabolism: Both hormones are processed in the liver (CYP3A4 and conjugation) and excreted via urine and faeces.
Kliovance is a continuous combined Hormone Replacement Therapy (HRT) that replaces the oestrogen lost after menopause while a progestogen safeguards the uterus. By mimicking natural hormonal regulation, it alleviates hot flushes, night sweats, and prevents osteoporosis in postmenopausal women with an intact womb.
Important Medical Advice
Stop Kliovance and seek immediate medical help if you experience: signs of a blood clot (swollen painful leg, sudden chest pain, breathing difficulty), jaundice (yellow skin/eyes), sudden severe headache or migraine-like symptoms, or signs of angioedema (swollen face/tongue, difficulty swallowing). Do not take Kliovance if you have unexplained vaginal bleeding, breast cancer, or a history of blood clots.
Chemical Composition & Molecular Structure of Kliovance
Kliovance film‑coated tablets contain two active pharmaceutical ingredients: estradiol hemihydrate (equivalent to 1 mg estradiol) and norethisterone acetate (0.5 mg). The excipients include lactose monohydrate (71.6 mg per tablet), maize starch, copovidone, talc, and magnesium stearate; the film‑coat consists of hypromellose, triacetin, and talc.
Structural & Physicochemical Properties
Estra-1,3,5(10)-triene-3,17β-diol
Natural oestrogen with high affinity for oestrogen receptors. Lipophilic (logP 3.0) allowing diffusion across cell membranes. Micronised form enhances oral absorption.
17α-ethynyl-19-nortestosterone acetate
Synthetic progestogen derived from 19-nortestosterone. Rapidly deacetylated to norethisterone, which binds progesterone and androgen receptors with high potency.
Key Pharmaceutical Characteristics
| Property | Estradiol | Norethisterone (active metabolite) |
|---|---|---|
| Molecular weight | 272.38 g/mol | 298.42 g/mol |
| Protein binding | ~98% (to SHBG & albumin) | ~96% (primarily albumin) |
| Oral bioavailability | ≈5% (extensive first-pass) | ≈64% (after deacetylation) |
| Receptor affinity | ERα/ERβ high | Progesterone receptor high; weak androgen/glucocorticoid |
📘 Pharmaceutical note: The lactose carrier is relevant for patients with rare hereditary galactose intolerance; consult your GP if you have sugar malabsorption.
Mechanism of Action: Dual Hormonal Pathway
Kliovance exerts its effects through two complementary pathways that mimic the physiological actions of ovarian hormones.
- Estradiol (oestrogenic component): After absorption, estradiol diffuses into target cells (hypothalamus, bone, urogenital tract, vascular endothelium) and binds to oestrogen receptors (ERα and ERβ). The receptor complex translocates to the nucleus, initiating gene transcription that:
– Reduces hypothalamic thermoregulatory instability → alleviates hot flushes and night sweats.
– Increases osteoblast activity and reduces bone resorption → prevents postmenopausal osteoporosis.
– Restores vaginal epithelium and urethral mucosa → improves urogenital atrophy symptoms. - Norethisterone acetate (progestogenic component): Rapidly deacetylated to norethisterone, it binds progesterone receptors in the endometrium. This action:
– Opposes estradiol-induced endometrial proliferation, converting the endometrium to a secretory or atrophic state.
– Prevents endometrial hyperplasia and reduces the risk of endometrial cancer (which is elevated with unopposed oestrogen).
– The continuous combined schedule ensures daily progestogen coverage, eliminating withdrawal bleeding and providing sustained endometrial safety.
| Effect | Estradiol | Norethisterone |
|---|---|---|
| Onset of symptom relief | 2–4 weeks (vasomotor) | Continuous protection from first dose |
| Endometrial impact | Stimulates growth | Suppresses growth, induces atrophy |
| Bone density effect | Increases mineral density | Additive effect via receptor cross-talk |
⚕️ Clinical insight: The continuous combined regimen is suitable only for women who have not had a period for at least 12 months, as it avoids the return of monthly bleeding and simplifies adherence.
Absorption & Distribution of Estradiol and Norethisterone
Following oral administration, both components are rapidly absorbed from the gastrointestinal tract. Estradiol undergoes extensive first‑pass metabolism in the gut wall and liver, resulting in low systemic bioavailability; micronisation improves absorption. Norethisterone acetate is swiftly deacetylated to norethisterone, which reaches peak plasma concentrations within 1–2 hours.
Absorption & peak levels
Estradiol: Tmax 3–7 hours; norethisterone: Tmax 1–2 hours. Steady state achieved after 3–5 days of daily dosing.
Distribution & tissue targeting
Both hormones are highly protein‑bound. Estradiol has a volume of distribution ~1.2 L/kg; norethisterone ~4 L/kg. Both accumulate in fat tissue and the endometrium, where they exert their pharmacological actions.
Metabolic Effects & Elimination Pathways
Estradiol metabolism: Primarily via CYP3A4 in the liver, estradiol is oxidised to estrone and estrone sulfate, then further hydroxylated to catechol estrogens. These metabolites are conjugated (glucuronidation, sulfation) and excreted in urine (≈60%) and faeces (≈40%). The terminal half‑life is 12–14 hours.
Norethisterone metabolism: Norethisterone acetate is deacetylated to norethisterone, which undergoes reduction (5α/5β) and hydroxylation via CYP3A4, followed by conjugation. Metabolites are mainly renally eliminated. The half‑life ranges from 5–9 hours.
⚠️ Metabolic caution: Severe hepatic impairment can reduce clearance of both hormones, potentially increasing systemic exposure. Concomitant use of CYP3A4 inducers (e.g., rifampicin, St John’s Wort) may reduce efficacy and cause irregular bleeding.
Clinical Efficacy in Menopause Symptom Relief and Osteoporosis Prevention
Kliovance is indicated for oestrogen deficiency symptoms in postmenopausal women ≥1 year since last natural period and for prevention of osteoporosis in women at high risk of fractures where alternatives are unsuitable.
- Vasomotor symptoms: In randomised controlled trials, moderate‑to‑severe hot flushes reduced by 80–90% within 12 weeks. Continuous combined regimen also improves sleep quality and mood disturbances.
- Urogenital atrophy: Estradiol restores vaginal pH, increases superficial epithelial cells, and reduces dyspareunia and urinary frequency.
- Bone protection: Kliovance increases lumbar spine and hip bone mineral density by 3–5% over 2 years, with fracture risk reduction comparable to other HRT preparations. Benefits persist as long as treatment continues.
- Endometrial safety: The daily progestogen component reduces the excess risk of endometrial hyperplasia and cancer to levels similar to non‑users, making it suitable for long‑term management.
Regular follow‑up (at least annually) is essential to reassess benefits and risks. The lowest effective dose should be used for the shortest duration consistent with treatment goals.
Kliovance FAQs
How quickly does Kliovance start working for hot flushes?
Many women notice improvement in hot flushes and night sweats within 2–4 weeks of starting Kliovance. Maximum benefit is typically achieved after 8–12 weeks of continuous use.
What should I do if I miss a dose of Kliovance?
If you miss a tablet by less than 12 hours, take it immediately. If more than 12 hours have passed, skip the missed dose and continue normally the next day. Do not double dose. Missing tablets may increase spotting or breakthrough bleeding.
Does Kliovance increase breast cancer risk?
Combined HRT like Kliovance is associated with a small increased risk of breast cancer, particularly with use beyond 5 years. The risk returns to baseline within a few years after stopping. Your doctor will discuss this based on your personal and family history.
Can I take Kliovance if I still have periods?
No. Kliovance is intended for women who have not had a natural period for at least 12 months (postmenopausal). If you have irregular periods, your doctor will usually recommend a sequential HRT instead.
What side effects are common when starting Kliovance?
Breast tenderness, nausea, headache, and irregular spotting are common during the first 3–6 months. These usually settle as your body adjusts. Persistent or heavy bleeding should be reviewed by your doctor.
Need Kliovance with Personalised HRT Guidance?
If you are experiencing moderate‑to‑severe menopausal symptoms and have not had a period for over a year, Kliovance may be a suitable continuous combined HRT option. A UK‑registered doctor can assess your suitability based on your medical history.
Secure Prescription & Next-Day Delivery
GPhC‑registered pharmacy | UK‑regulated doctors | Discreet packaging | Ongoing clinical support
Start Menopause ConsultationRelated Kliovance Guides
Medical Content Manager
Nabeel is a co-founder, and medical content manager of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up-to-date.
Medical Doctor
Dr. Feroz is a GMC-registered doctor and a medical reviewer at Chemist Doctor. He oversees acute condition and urgent care guidance.
Medical Director
Usman is a co-founder, and medical director of Chemist Doctor. He leads the organisation's strategic vision, bridging clinical and operational priorities.
Review Date: 27 March 2026
Next Review: 27 September 2026
Published on: 27 March 2026
Last Updated: 27 March 2026